Company news

Aprea Therapeutics, Inc. news in 2021

Aprea Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting

December 12, 2021

Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies

December 8, 2021

Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations

November 7, 2021

Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program

August 11, 2021

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

August 4, 2021

Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML

July 20, 2021

Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint

June 15, 2021

Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations

May 5, 2021

Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021

April 15, 2021

Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)

April 7, 2021

Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations

March 15, 2021

Decks in 2021